Morgan Stanley Maintains Equal-Weight on Certara, Lowers Price Target to $25
Morgan Stanley analyst Vikram Purohit maintains Certara (NASDAQ:CERT) with a Equal-Weight and lowers the price target from $27 to $25.
Barclays Maintains Overweight on Certara, Lowers Price Target to $26
Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $48 to $26.
68 Biggest Movers From Yesterday
Gainers
ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows.
Recap: Certara Q4 Earnings
Certara (NASDAQ:CERT) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:15 PM.
Here's what investors need to know about the announcement.
Earnings
Certara missed estimated earnings by 87.5%, reporting an EPS of $0.01 versus an estimate of $0.08.
UPDATE: Certara Q4 Adj. EPS $0.01 Misses $0.08 Estimate, Sales $75.35M Miss $83.26M Estimate
Certara (NASDAQ:CERT) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.08 by 87.5 percent. This is a 88.89 percent decrease over earnings of $0.09 per share from the same
Certara Q4 EPS $(0.06) Misses $0.08 Estimate, Sales $75.34M Miss $83.26M Estimate
Certara (NASDAQ:CERT) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.08 by 175 percent. This is a 166.67 percent decrease over earnings of $0.09 per share from the same
Certara’s Earnings Outlook
Certara (NASDAQ:CERT) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement.
Analysts estimate that Certara will report an earnings per share (EPS) of $0.08.
Certara Reports FDA Licenses Co.’s Immunogenicity Simulator
Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has licensed Certara’s Immunogenicity (IG) Simulator to research and evaluate
